磷酸咯萘啶普通片与肠溶片对恶性疟疗效的比较

THERAPEUTIC EFFECT OF PYRONARIDINE IN PLAIN TABLETS AND ENTERIC-COATED TABLETS IN FALCIPARUM MALARIA PATIENTS

根据药物动力学研究结果及推荐的理论剂量,应用咯萘啶普通片0.8g,2天疗法(d_(1)0.5g,d_(?)0.3g)与现用方案肠溶片1.2g,2天疗法(d_(1)0.4g×2,d_(2)0.4g)治疗现症恶性疟病例各32例,其退热时间分别为27.0±14.1和30.2±13.8h(P>0.05),原虫转阴时间分别为57.2士10.2和57.9±8.7h,前者治愈率为100％,后者有2例复燃,副反应率各为18.8和28.1％,程度均较轻,无需特殊处理。结果表明,普通片的药量降低1/3,同样可达到现用方案的疗效,同时,副反应亦轻,值得进一步探讨。

A new oral dosage regimen and formulation of pyronaridine basing on tne pharma-cokinetic studies and a theoretical dosage regimen reported pnviously, was clinically evaluated for its therapeutic and undesirable effects on falciparum malaria patients in west Hainan Province, where chloroqine-resistant falciparum malaria was prevalent. 32 cases were treated with pyronaridine by tne new dosage regimen of 0.5g in d1 and 0.3g in d2 in plain tablets(groupA), while additional 32 patients received enteric-coated tablets of pyronaridine by the current dosage regimen as a control(groupB), which was 0.4g×2 on dn and 0.4g on d2. The average fever clearance time for A and B groups was 27.0 ± 14.1 and 30.2±13.8h respectively(P>0.05),and the clearance time for asex-ual parasites was 57.2±10.2 and 57.9±8.7h. Upon 28d following-up examination, the cure rates were found to be 100% in group A and 93.8% in group B. The undesirable responses were recorded in 18.8% of group A patients(6/32), and 28.1% of group B (9/32)respectively, and they were light and tolerable and short in time duration. It was shown that the new dosage regimen of pyronaridine could retain the same therapeutic effect as that currently used, although the total dose was reduced by one third. Hence, an important basis was provided for more rational use and further study of pyronaridine in malaria therapy.